ALXO250117P3000
- 0.00
- 0.000.00%
ALX Oncology Newsroom
Jefferies Downgrades ALX Oncology(ALXO.US) to Hold Rating, Cuts Target Price to $2
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
ALX Oncology Shares Are Trading Lower After Jefferies Downgraded the Stock From Buy to Hold and Cut Its Price Target From $12 to $2.
Top Midday Decliners
Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2
Express News | ALX Oncology Holdings Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $2 From $12
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdingsto Overweight
ALX Oncology to Present Updated Results From Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients With HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
ALX Oncology Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Promising Evorpacept Data Bolsters Buy Rating for ALX Oncology Holdings
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination With Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Press Release: ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Express News | Cantor Fitzgerald Reiterates Overweight on ALX Oncology Holdings
LifeSci Capital Maintains ALX Oncology(ALXO.US) With Hold Rating
ALX Oncology Highlights Promising Trial Results
Stifel Maintains ALX Oncology(ALXO.US) With Hold Rating, Maintains Target Price $3